FINWIRES · TerminalLIVE
FINWIRES

Research Alert: CFRA Maintains Buy Rating On Shares Of Guardant Health

By

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

We raise our 12-month target by $28 to $140, reflecting a 9.6x multiple of our 2026 EV/sales estimate, below GH's one-year historical forward average of 10.6x and above the three-year forward average of 7.6x. We narrow our 2026 loss per share estimate by $0.01 to -$1.42 and narrow 2027's by $0.12 to -$0.62. We think GH's strengthening growth outlook gains support from yesterday's FDA approval of the updated Guardant360 Liquid CDx test, which incorporates a 100x greater genomic footprint than the previous version and supports significantly greater tumor sensitivity, with a rapid turnaround time of just seven days. We think the approval may expand GH's addressable market and support higher testing volumes, supported by recent momentum from partnerships with pharma and lab testing firms, while potentially accelerating GH's path toward profitability (anticipated around late 2027 to early 2028).

Related Articles

Research

Research Alert: Nordson: Q2 Fy 26 Results Top Expectations, Guidance Lifted

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:NDSN delivered strong Q2 FY 26 (Oct.) results, with sales of $741M (+8% Y/Y) and adjusted EPS of $2.86 (+18% Y/Y), beating consensus of $2.85. Organic sales growth of 7% was broad-based across segments, with favorable foreign exchange rates contributing an additional 3%. Order backlog growth of 18% was encouraging, reflecting demand recovery that we see providing stronger visibility and positioning NDSN well for growth. Management raised full-year guidance for both sales and adjusted EPS as demand conditions brighten. Segment performance was mixed, with Industrial Precision Solutions achieving 10% sales growth but experiencing 100-bps EBITDA margin compression to 35%. Advanced Tech Solutions was the standout performer, posting 8% organic growth while expanding EBITDA margins 200 bps to 27%, driven by strong electronics demand. Free cash flow conversion was robust at 113% of adjusted net income, enabling the strategic CapstanAG acquisition to expand precision agriculture capabilities.

$NDSN
Research

Research Alert: Urban Outfitters Q1 Beats Estimates On Namesake And Free People Strength

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:URBN delivered record Q1 FY 27 results with net sales of $1.48B (+11.4% Y/Y), $20M above estimates, and EPS of $1.30 (+12.1% Y/Y), $0.16 above consensus. Performance was driven by broad-based strength across segments, with Retail sales advancing +8.0% Y/Y and comparable sales increasing +5.6% Y/Y, led by Free People (+9.8% Y/Y) and Urban Outfitters (+9.3% Y/Y). The Subscription segment surged +34.5% Y/Y to $167.3M, while the company repurchased $300M in shares during the quarter. Management expressed confidence in the company's trajectory, citing engaged customers responding to compelling fashion trends. Gross margin contracted 16 bps to 36.6% due to a prior-year gain, though underlying margin improved 20 bps from better markdown discipline. We believe the impressive growth in the subscription business, which is becoming a larger portion of total revenues, supports the investment thesis as URBN continues to diversify beyond traditional retail.

$URBN
Research

Research Alert: Nvda: Jul-q Guide Well Above Expectations; Returning More Cash To Shareholders

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:NVDA posted Apr-Q revenue of $81.6B (+85% Y/Y, +20% Q/Q), ahead of our $79B expectation, with Data Center revenue of $75.2B (+92%, +21%) representing over 90% of total revenue and $2B above expectations. Non-GAAP EPS of $1.87 (+140% Y/Y) beat the $1.78 consensus, while gross margins remained stable at 75.0%. We view the new reporting framework splitting Data Center into balanced Hyperscale ($37.9B) and ACIE ($37.4B) segments as demonstrating expansion beyond traditional hyperscalers into sovereign AI and enterprise applications. Jul-Q guidance of $91.0B (+/- 2%) came well ahead of our $87B expectation, indicating continued sequential growth momentum. NVDA announced an additional $80B share repurchase authorization and dividend increase to $0.25 per share, signaling confidence in the business trajectory. We continue to anticipate the company will generate over $400B in FCF over the next eight quarters and think returning more cash to shareholders is warranted as top-line growth decelerates over time.

$NVDA